Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
IPO Year: 1991
Exchange: NASDAQ
Website: vrtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2025 | Outperform → Peer Perform | Wolfe Research | |
| 5/6/2025 | $503.00 | Outperform → Market Perform | Leerink Partners |
| 4/22/2025 | $535.00 | Overweight | Cantor Fitzgerald |
| 2/12/2025 | $408.00 → $424.00 | Sell → Hold | Canaccord Genuity |
| 2/11/2025 | Sell → Hold | Canaccord Genuity | |
| 1/30/2025 | $460.00 | Overweight → Equal Weight | Wells Fargo |
| 12/20/2024 | $600.00 → $535.00 | Buy | H.C. Wainwright |
| 12/19/2024 | Outperform → Perform | Oppenheimer | |
| 12/9/2024 | $500.00 → $550.00 | Hold → Buy | Jefferies |
| 11/14/2024 | $575.00 | Buy | Citigroup |
Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform
Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00
Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00
Canaccord Genuity upgraded Vertex Pharma from Sell to Hold and set a new price target of $424.00 from $408.00 previously
Canaccord Genuity upgraded Vertex Pharma from Sell to Hold
Wells Fargo downgraded Vertex Pharma from Overweight to Equal Weight and set a new price target of $460.00
H.C. Wainwright reiterated coverage of Vertex Pharma with a rating of Buy and set a new price target of $535.00 from $600.00 previously
Oppenheimer downgraded Vertex Pharma from Outperform to Perform
Jefferies upgraded Vertex Pharma from Hold to Buy and set a new price target of $550.00 from $500.00 previously
Citigroup initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $575.00
— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award "for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives." Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa. "For more than 20 years, Paul and the team of dedicated Vertex researchers have focused on discovering and developing breakthrough therapies for people living with cystic fibrosis (CF). P
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - - Continue to progress multiple novel, research-stage immunoprotective approaches - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET. Charles Wagner, Executive Vice President and Chief Financial Officer, and Dr. Altshuler will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:00 a.m. ET. Susie Lisa, Senior Vice Pres
AM Best has assigned a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of "a" (Excellent) to Torreyana Insurance Company, Inc. (TIC) (Burlington, VT). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect TIC's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Torreyana's function as the only captive insurer for Vertex Pharmaceuticals Incorporated (Vertex) (NASDAQ:VRTX), a global pharmaceutical company. As Torreyana insures or reinsures Vertex's global liability and pr
— Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain — — Diverse late-stage clinical pipeline accelerates with four programs in pivotal development — — Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating Officer; Duncan McKechnie, SVP and current head of North America Commercia
- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 - Vertex Pharmaceuticals (NASDAQ:VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. It means that eligible SCD patients in England now have access to the therapy following t
-- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potentia
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcas
— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals First Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast
— Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S. for moderate-to-severe acute pain — — Diverse late-stage clinical pipeline accelerates with four programs in pivotal development — — Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating Officer; Duncan McKechnie, SVP and current head of North America Commercia
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcas
– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS) – – Placebo arm showed similar within-group reduction in NPRS – – Suzetrigine was generally well tolerated – – Advancement to Phase 3 in painful lumbosacral radiculopathy planned, pending discussions with regulators – – Vertex to host investor call on December 19 at 8:00 a.m. ET – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. "The third quarter marked anot
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived web
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of January 30, 2025 — — Advancing broad and deep clinical pipeline with multiple milestones expected in H2:24 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the second quarter e
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived
— Product revenue of $2.69 billion, a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sciences, including povetacicept, a Phase 3-ready asset in IgA nephropathy and potential pipeline-in-a-product — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the first quarter en
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022. Mr. Biller will report directly to Vertex's Chief Executive Officer and President, Reshma Kewalramani, M.D., and join the company's Executive Committee. In this role, Mr. Biller will oversee all of Vertex's global legal and compliance functions. "Jonathan is an outstanding addition to Vertex with his deep legal, industry and business experience, and I am delighted to welcome him to the company," said Dr. Kewalramani. "Jonathan will lead an extraordinarily talented legal and compliance team and support our continued growth as we expand
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Stuart A. Arbuckle has been appointed as the company's Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex's Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year. "This is an exciting time for Vertex, as we continue to expand access to our cystic fibrosis portfolio around the world and prepare to bring forward new therapies with the potential to transform the treatment of multiple serious diseases," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Ver
Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors
For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain. Journavx is the first dr
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-2) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 217660, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug ORKAMBI (SUPPL-5) with active ingredient IVACAFTOR; LUMACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 211358, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug SYMDEKO (COPACKAGED) (SUPPL-11) with active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 210491, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug KALYDECO (SUPPL-17) with active ingredient IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 207925, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug ORKAMBI (SUPPL-17) with active ingredient IVACAFTOR; LUMACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 206038, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug KALYDECO (SUPPL-16) with active ingredient IVACAFTOR has changed to 'Approval' on 05/03/2023. Application Category: NDA, Application Number: 207925, Application Classification: Efficacy
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (ORIG-1) with active ingredient ELEXACAFTOR;TEZACAFTOR;IVACAFTOR;IVACAFTOR has changed to 'Approval' on 04/26/2023. Application Category: NDA, Application Number: 217660, Application Classification: Type 3 - New Dosage Form
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
DEFA14A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
DEF 14A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
S-3ASR - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
10-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
SCHEDULE 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)